Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
Peter Nash(Griffith University), Jacob Aelion(Middle Tennessee Research Institute), Jessica A. Walsh(VA Salt Lake City Healthcare System), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Kamal Ohson(Memorial University of Newfoundland), Juan J. Gómez‐Reino(Hospital Clínico Universitario de Valencia), Dianne Nguyen(Baylor College of Medicine), Lichen Teng(Harbin Medical University)
Cited by 88
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
|Annals of the Rheumatic Diseases|2016|286
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
New Sequence Variants in HLA Class II/III Region Associated with Susceptibility to Knee Osteoarthritis Identified by Genome-Wide Association Study
|PLoS ONE|2010|125
A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis
|Arthritis Research & Therapy|2015|116